Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 13/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.47 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.47 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.47 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.47 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.47 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.47 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3749146 | 0.86 | FAAH (0.68) | FAAHKMT2APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL3749133 | 0.84 | KMT2A (0.61) | FAAHKMT2A | |
| SCHEMBL3753891 | 0.83 | FAAH (0.55) | FAAH | |
| SCHEMBL4187012 | 0.82 | FAAH (0.78) | FAAH | |
| SCHEMBL3749375 | 0.82 | FAAH (0.67) | FAAHKMT2A | |
| SCHEMBL3753895 | 0.82 | FAAH (0.57) | FAAHKMT2A | |
| SCHEMBL3748462 | 0.82 | FAAH (0.58) | FAAHKMT2AMCHR1 | |
| SCHEMBL3747939 | 0.81 | FAAH (0.66) | FAAHKMT2A | |
| SCHEMBL3759867 | 0.81 | FAAH (0.59) | FAAHKMT2A | |
| SCHEMBL3747193 | 0.80 | FAAH (0.70) | FAAHKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | claimed |
| EP-2023728-A2 | OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2009-02-18 | — | — | EP | claimed |
| WO-2007140005-A2 | OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | WO | claimed |
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | FAAH, FAAH2, APEH | FAAH 1/4885KMT2A 536/4885PRKAB2 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.